Yue Wang1, Bo Dai1, Dingwei Ye1. 1. Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China.
Abstract
BACKGROUND: CHEK2 encodes for a G2 checkpoint kinase which plays a critical role in DNA repair. Its mutation confers an increased risk of breast cancer. It has also been suggested to increase risks of prostate cancer, but its involvement with this type of cancer has not been confirmed. METHODS: We performed a systematic review and meta-analysis to clarify the association between CHEK2 1100delC, IVS2+1G>A, I157T mutation and risk of Prostate Cancer. A comprehensive, computerized literature search of PubMed until December 27, 2014 was carried out. Eligible studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated using the fixed effects model or random effects model according to heterogeneity between studies. RESULTS: Eight eligible studies were included in the analysis, all were retrospective studies. The overall meta-analysis demonstrated that the CHEK2 1100delC mutation (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) and I157T missense mutation (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00) was associated with higher risk of Prostate Cancer, and CHEK2 1100delC mutation is irrelevant to familial aggregation phenomenon of prostate cancer (OR 1.59; 95% confidence interval: 0.79-3.20; P = 0.20). The IVS2+1G>A mutation is also irrelevant to Prostate Cancer (OR = 1.59, 95% CI = 0.93-2.71, P = 0.09). None of the single studies materially altered the original results and no evidence of publication bias was found. CONCLUSION: CHEK2 1100delC mutation and I157T missense mutation in males indicates higher risk of Prostate Cancer, but there's no evidence to prove the CHEK2 1100delC mutation was associated with Familial prostate cancer.
BACKGROUND:CHEK2 encodes for a G2 checkpoint kinase which plays a critical role in DNA repair. Its mutation confers an increased risk of breast cancer. It has also been suggested to increase risks of prostate cancer, but its involvement with this type of cancer has not been confirmed. METHODS: We performed a systematic review and meta-analysis to clarify the association between CHEK21100delC, IVS2+1G>A, I157T mutation and risk of Prostate Cancer. A comprehensive, computerized literature search of PubMed until December 27, 2014 was carried out. Eligible studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated using the fixed effects model or random effects model according to heterogeneity between studies. RESULTS: Eight eligible studies were included in the analysis, all were retrospective studies. The overall meta-analysis demonstrated that the CHEK21100delC mutation (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) and I157T missense mutation (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00) was associated with higher risk of Prostate Cancer, and CHEK21100delC mutation is irrelevant to familial aggregation phenomenon of prostate cancer (OR 1.59; 95% confidence interval: 0.79-3.20; P = 0.20). The IVS2+1G>A mutation is also irrelevant to Prostate Cancer (OR = 1.59, 95% CI = 0.93-2.71, P = 0.09). None of the single studies materially altered the original results and no evidence of publication bias was found. CONCLUSION:CHEK21100delC mutation and I157T missense mutation in males indicates higher risk of Prostate Cancer, but there's no evidence to prove the CHEK21100delC mutation was associated with Familial prostate cancer.
Entities:
Keywords:
CHEK2 mutation; Prostate cancer; risk of prostate cancer
Authors: Marjo van Puijenbroek; Christi J van Asperen; Anneke van Mil; Peter Devilee; Tom van Wezel; Hans Morreau Journal: J Pathol Date: 2005-06 Impact factor: 7.996
Authors: Haeryoung Kim; Burcu Saka; Spencer Knight; Michael Borges; Erica Childs; Alison Klein; Christopher Wolfgang; Joseph Herman; Volkan N Adsay; Ralph H Hruban; Michael Goggins Journal: Clin Cancer Res Date: 2014-01-31 Impact factor: 12.531
Authors: G Zoppoli; S Solier; W C Reinhold; H Liu; J W Connelly; A Monks; R H Shoemaker; O D Abaan; S R Davis; P S Meltzer; J H Doroshow; Y Pommier Journal: Oncogene Date: 2011-07-18 Impact factor: 9.867
Authors: Rogier A Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hans Morreau; Jan G M Klijn; Nicoline Hoogerbrugge; Marjolein J L Ligtenberg; Christi J van Asperen; Hans F A Vasen; Carel Meijers; Hanne Meijers-Heijboer; Truuske H de Bock; Cees J Cornelisse; Peter Devilee Journal: Cancer Res Date: 2003-12-01 Impact factor: 12.701
Authors: Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman Journal: Int J Cancer Date: 2007-12-15 Impact factor: 7.396
Authors: Hanne Meijers-Heijboer; Juul Wijnen; Hans Vasen; Marijke Wasielewski; Anja Wagner; Antoinette Hollestelle; Fons Elstrodt; Renate van den Bos; Anja de Snoo; Grace Tjon A Fat; Cecile Brekelmans; Shantie Jagmohan; Patrick Franken; Paul Verkuijlen; Ans van den Ouweland; Pamela Chapman; Carli Tops; Gabriela Möslein; John Burn; Henry Lynch; Jan Klijn; Riccardo Fodde; Mieke Schutte Journal: Am J Hum Genet Date: 2003-04-10 Impact factor: 11.025
Authors: E H Seppälä; T Ikonen; N Mononen; V Autio; A Rökman; M P Matikainen; T L J Tammela; J Schleutker Journal: Br J Cancer Date: 2003-11-17 Impact factor: 7.640
Authors: Zhengyi Deng; Kanhua Yin; Yujia Bao; Victor Diego Armengol; Cathy Wang; Ankur Tiwari; Regina Barzilay; Giovanni Parmigiani; Danielle Braun; Kevin S Hughes Journal: JCO Clin Cancer Inform Date: 2019-08
Authors: Veda N Giri; Karen E Knudsen; William K Kelly; Heather H Cheng; Kathleen A Cooney; Michael S Cookson; William Dahut; Scott Weissman; Howard R Soule; Daniel P Petrylak; Adam P Dicker; Saud H AlDubayan; Amanda E Toland; Colin C Pritchard; Curtis A Pettaway; Mary B Daly; James L Mohler; J Kellogg Parsons; Peter R Carroll; Robert Pilarski; Amie Blanco; Ashley Woodson; Alanna Rahm; Mary-Ellen Taplin; Thomas J Polascik; Brian T Helfand; Colette Hyatt; Alicia K Morgans; Felix Feng; Michael Mullane; Jacqueline Powers; Raoul Concepcion; Daniel W Lin; Richard Wender; James Ryan Mark; Anthony Costello; Arthur L Burnett; Oliver Sartor; William B Isaacs; Jianfeng Xu; Jeffrey Weitzel; Gerald L Andriole; Himisha Beltran; Alberto Briganti; Lindsey Byrne; Anne Calvaresi; Thenappan Chandrasekar; David Y T Chen; Robert B Den; Albert Dobi; E David Crawford; James Eastham; Scott Eggener; Matthew L Freedman; Marc Garnick; Patrick T Gomella; Nathan Handley; Mark D Hurwitz; Joseph Izes; R Jeffrey Karnes; Costas Lallas; Lucia Languino; Stacy Loeb; Ana Maria Lopez; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark Mann; Patrick Mille; Martin M Miner; Todd Morgan; Jose Moreno; Lorelei Mucci; Ronald E Myers; Sarah M Nielsen; Brock O'Neil; Wayne Pinover; Peter Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Charles Ryan; Howard Sandler; Matthew Schiewer; E Michael D Scott; Brittany Szymaniak; William Tester; Edouard J Trabulsi; Neha Vapiwala; Evan Y Yu; Charnita Zeigler-Johnson; Leonard G Gomella Journal: J Clin Oncol Date: 2020-06-09 Impact factor: 44.544
Authors: Roderick Clark; Miran Kenk; Kristen McAlpine; Emily Thain; Kirsten M Farncombe; Colin C Pritchard; Robert Nussbaum; Alexander W Wyatt; Johann de Bono; Danny Vesprini; Yvonne Bombard; Justin Lorentz; Steven Narod; Raymond Kim; Neil Fleshner Journal: Can Urol Assoc J Date: 2021-12 Impact factor: 1.862